Table 1

CDA reinforces immune regulation to attenuate antitumor responses

GroupCDACo-treatment
(with CDA)		Induced ICP pathwaysOutcomes
Survival*Relapse†Immunity
αPD-1IDOiCOX2iPD-L1IDOCOX2
A–     0/46– 
B+   +++11/470/110/11‡
C+ +    ++15/1515/15–
D1
D2
D3		+
+
+		 1MT
NLG
BMS		 +
+
+		+
+
+		5/8
4/8
14/14		0/2
0/4
14/14		–
E++BMS   8/98/8–
F1
F2		+
+		  +
+		+
+		-
-		 15/15
8/9		0/15
0/8		15/15‡
8/8§
G+ Small LLC tumors (~100 mm3) 15/150/1515/15‡

  • Numbers represent total number of mice from combined experiments.

  • *No. of mice surviving to end point (>60 days).

  • †No. of mice with tumors at end points (day 60 for groups A-F1, day 30 for group F2).

  • ‡No. of mice resistant to LLC re-challenge at day 60.

  • §No. of mice resistant to primary and distal tumor growth (abscopal effects).

  • CDA, cyclic diadenyl monophosphate; COX2i, cyclooxygenase-2 inhibitor; ICP, immune checkpoint; IDOi, indoleamine 2,3 dioxygenase inhibitor; LLC, Lewis lung carcinoma; PD-1, programmed death-1; PD-L1, programmed death ligand-1.